Technical Analysis for VTGN - VistaGen Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 1.04 -5.45% -0.06
VTGN closed down 5.45 percent on Friday, September 13, 2019, on 1.46 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical VTGN trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Wide Range Bar Range Expansion 0.00%
Upper Bollinger Band Walk Strength 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 200 DMA Bullish -5.45%
Doji - Bearish? Reversal -5.45%
Upper Bollinger Band Walk Strength -5.45%

Older signals for VTGN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary new chemical entities (NCEs) for internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and liver cells derived from hPSC technology. The company is also involved in the development of CardioSafe 3D, an in vitro bioassay system for predicting potential cardiotoxicity of new chemical entities (NCEs), including drug rescue NCEs; and LiverSafe 3D, a bioassay system to predict potential liver toxicity of new drug candidates, including potential drug metabolism issues and adverse drug-drug interactions. It has strategic collaborations with University Health Network for hPSC technology research and development; Synterys, Inc. to design, produce, and analyze drug rescue NCEs; and Cato Research, Ltd. for regulatory expertise and clinical development support. The company also has cooperative research and development agreement with the U.S. National Institute of Mental Health for the Phase II clinical study of AV-101. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Health Biopharmaceutical Pharmaceutical Industry Diseases Drug Discovery Clinical Trial Disorders Health Sciences Regenerative Medicine Pharmaceutical Sciences Major Depressive Disorder Antidepressants Treatment Of Major Depressive Disorder Clinical Pharmacology Chemical Entities Drug Metabolism Nmda Receptor Antagonists
Is VTGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.44
52 Week Low 0.38
Average Volume 302,400
200-Day Moving Average 1.0785
50-Day Moving Average 0.6497
20-Day Moving Average 0.757
10-Day Moving Average 0.8966
Average True Range 0.101
ADX 39.72
+DI 31.6169
-DI 14.5353
Chandelier Exit (Long, 3 ATRs ) 0.877
Chandelier Exit (Short, 3 ATRs ) 0.783
Upper Bollinger Band 1.1058
Lower Bollinger Band 0.4082
Percent B (%b) 0.91
BandWidth 92.153237
MACD Line 0.119
MACD Signal Line 0.0776
MACD Histogram 0.0414
Fundamentals Value
Market Cap 9.75 Million
Num Shares 9.38 Million
EPS -1.35
Price-to-Earnings (P/E) Ratio -0.77
Price-to-Sales 7.65
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.36
Resistance 3 (R3) 1.37 1.27 1.30
Resistance 2 (R2) 1.27 1.19 1.27 1.28
Resistance 1 (R1) 1.16 1.14 1.11 1.15 1.27
Pivot Point 1.06 1.06 1.04 1.06 1.06
Support 1 (S1) 0.95 0.98 0.90 0.94 0.81
Support 2 (S2) 0.85 0.93 0.85 0.80
Support 3 (S3) 0.74 0.85 0.78
Support 4 (S4) 0.73